Newsletter #3: Scaling new heights
« Scaling New Heights » isn’t just a recap: it’s a celebration of collective progress. From market expansion and production growth to training, innovation, and our unwavering commitment to quality, this edition captures the momentum driving us forward.
Our newsletter
3rd edition
« Scaling New Heights » isn’t just a recap: it’s a celebration of collective progress. From market expansion and production growth to training, innovation, and our unwavering commitment to quality, this edition captures the momentum driving us forward.
It reflects the shared ambition of every department: recruiting new talent, advancing medical education, and strengthening partnerships across the sports medicine landscape.
👇 Have a read and see how we’re shaping the future, together !
A message from our CEO, Hervé Legrand
As we enter the second half of 2025, I’d like to take the opportunity of this 3rd Newsletter to reflect—but above all, to look ahead with determination and enthusiasm. Thanks to your continued trust and the dedication of our teams, we’re growing faster, building stronger, and preparing more intelligently for what lies ahead.
Over the past four years, Movmedix has recorded an average growth of over 25%—well above the sports medicine market, which grows at around 7 to 8% per year. This strong performance is a clear signal: our solution meets a real need, and we are moving in the right direction.
In 2024, we focused on strengthening our foundations: 10 new talents joined us, our organization was further structured, we returned to growth (+23%) driven by strong momentum in China and internationally, and over 700 surgeons were trained. We also opened three new markets and launched our R&D roadmap.
At the same time, the ligament repair landscape is evolving rapidly. New players are emerging, technologies are advancing, and expectations are rising. It’s an exciting time for our sector—but also a reminder that we must stay alert. We need to remain agile, innovative, and focused to maintain our leadership.
Our priorities for 2025 are clear and ambitious:
• Continue our growth, with a +30% target and an expanded training program.
• Expand our geographic presence, with commercial launches in new countries, continued regulatory registrations, and preparation for our U.S. market entry in 2026.
• Accelerate innovation, with the launch of the 4th Generation Phase 2 clinical study, the creation of a Scientific Advisory Board, and faster development of or 5th Generation.
• Strengthen our production capabilities to sustainably support increasing demand.
These goals are ambitious—and so are we. Most importantly, we know we are not alone. Our partners, surgeons, and investors play a vital role in this journey.
Thank you for your trust, your engagement, and your shared ambition to advance ligament repair.
Let’s keep building the future of Movmedix—together.
About Movmedix
Driven by our vision to restore infinite mobility to patients suffering from soft tissue injuries, Movmedix continues to evolve toward becoming a global leader in sports medicine. With more than three decades of expertise, we have been at the forefront of the artificial ligament field — pioneering free-fibre technology and designing implants tailored to specific clinical indications.
Building on the strong legacy of our LARS® (Ligament Advanced Reinforcement System) product range, we remain committed to developing innovative and disruptive solutions that address the evolving needs of surgeons and improve patient outcomes worldwide.
